<table width="477.9pt" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="15%"></col>
<col width="85%"></col>
<tbody>
<tr stylecode="Toprule">
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="middle">
<paragraph>
<content stylecode="bold">Bleeding Times </content>
</paragraph>
</td>
</tr>
<tr stylecode="Toprule">
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Naproxen may decrease platelet aggregation and prolong bleeding time. </paragraph>
</td>
</tr>
<tr stylecode="Toprule">
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>This effect should be kept in mind when bleeding times are determined. </paragraph>
</td>
</tr>
<tr stylecode="Toprule">
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Porter-Silber Test </content>
</paragraph>
</td>
</tr>
<tr stylecode="Toprule">
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-di-nitrobenzene used in this assay. </paragraph>
</td>
</tr>
<tr stylecode="Toprule">
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="bottom">
<paragraph>Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used. </paragraph>
</td>
</tr>
<tr stylecode="Toprule">
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Urinary Assays of 5-hydroxy indoleacetic acid (5HIAA) </content>
</paragraph>
</td>
</tr>
<tr stylecode="Toprule">
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA). </paragraph>
</td>
</tr>
<tr stylecode="Toprule">
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule " valign="middle">
<paragraph>This effect should be kept in mind when urinary 5-hydroxy indoleacetic acid is determined. </paragraph>
</td>
</tr>
</tbody>
</table>